Radiopharm Theranostics Ltd (RADX) Accumulated Expenses (2024 - 2025)
Radiopharm Theranostics (RADX) posted quarterly Accumulated Expenses of $1.8 million for Q2 2025, up 59.07% year-over-year from $1.1 million in Q2 2024, and up 59.07% quarter-over-quarter from $1.1 million in Q2 2024.
Radiopharm Theranostics Ltd (RADX) Accumulated Expenses (2024 - 2025) Analysis & Trends
Radiopharm Theranostics (RADX) has reported Accumulated Expenses for 2 consecutive years, with $1.8 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Accumulated Expenses rose 59.07% year-over-year to $1.8 million; the TTM figure through Jun 2025 stood at $1.8 million (up 59.07% YoY), while the FY2025 annual figure was $450104.0, up 12.59% from the prior year.
- Accumulated Expenses climbed to $1.8 million in Q2 2025 per RADX's latest filing, from $1.1 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $1.8 million in Q2 2025 and bottomed at $1.1 million in Q2 2024.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1.76 Mn |
| Jun 30, 2024 | 1.11 Mn |